1 min read
Add as a preferred source on GoogleImpella Analyses Show Lower Mortality in High-Risk Heart Procedures
The analyses compared mortality among patients receiving the heart-pump support with rates reported in the recent CHIP-BCIS3 trial.
Johnson & Johnson said three clinical analyses found lower mortality rates among patients who received Impella support for high-risk coronary procedures than the rates reported in the recent CHIP-BCIS3 trial.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.